Federal prosecutors say two American Senior Communities executives and two other men orchestrated a scheme that used kickbacks and shell companies to defraud American Senior Communities and federal health care programs out of millions of dollars.
The “toxic” office environment at a small St. Vincent Health office had broken out during an unprecedented wave of acquisitions of physician practices in central Indiana.
Eli Lilly and Co. shares rose sharply Thursday morning after the company presented a better-than-expected 2017 forecast nearly a month after it had announced the failure of a key Alzheimer’s treatment in testing.
The company’s announcement reassured investors in the wake of last month’s news that the Alzheimer’s drug solanezumab had failed to demonstrate effectiveness during a large-scale clinical trial.
The point of chemo is to cure me. But these are not gentle chemicals. They sweep through my body like a tornado, with side effects that range from annoying to horrendous. But I have no choice.
Eli Lilly and Co. will bypass insurance companies to offer a discount on its best-selling insulin products for patients who lack health coverage or have high deductibles that require them to pay the full cost of some medications.
The gift is the largest to the IU School of Medicine by an alumnus. The medical school will use the money to establish the Brown Center for Immunotherapy to fight some of the world’s toughest diseases.
A new report by the Centers for Disease Control and Prevention is pushing states with high Medicaid smoking rates to do more to encourage enrollees to quit and live longer.
The Indianapolis-based company, which last month struck out in a late-stage clinical trial for a potential Alzheimer’s drug called solanezumab, announced Friday a collaboration with AstraZeneca to develop another possible treatment for the mind-robbing disease.
An Indiana state official in charge of regulatory oversight of nursing homes and residential care facilities has been barred from taking a job at a private company that runs senior living communities over ethics concerns.
President-elect Donald Trump promised to drive down the cost of medicines, defying investors who saw a boon in his election last month and injecting himself again into a contentious economic debate.
In a few days, a new type of knockoff medicine will upend a $10 billion diabetes-drug market and exacerbate a brutal price war between some of its biggest players.
The FDA says the Indianapolis-based drugmaker and its partner can make an important label claim on its new diabetes drug—a move analysts say could give sales a big boost.
The company has requested a tax break from Indianapolis officials on the project that would save it about $484,000 over eight years.
With drug companies under fire, the world’s largest insulin maker plans to limit price increases and introducing a model that ties the cost of medicines to the results they deliver.
Eli Lilly and Co. plans to lay off hundreds of U.S. sales representatives in coming months, following the disappointing failure of an experimental drug for Alzheimer’s disease announced last week.
Anthem Inc. fired back against U.S. claims that the health insurer’s planned $48 billion takeover of rival Cigna Corp. will undermine competition.
The $6.3 billion bill would let the Food and Drug Administration approve drugs and medical devices more quickly and bolster federal mental health programs.
President-elect Donald Trump on Tuesday said he’ll nominate Seema Verma, founder of Indianapolis-based SVC Inc. and architect of the Healthy Indiana Plan, as his pick for administrator of the Centers for Medicare and Medicaid Services.
Analysts are all over the map on how investors should react to the Indianapolis-based drugmaker’s news that a promising drug failed to help patients.
